Want to create an interactive transcript for this episode?
Podcast: PeerView Clinical Pharmacology CME/CNE/CPE Video
Episode: James F. Howard Jr., MD - A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes
Description: Go online to PeerView.com/VZG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disorder that is highly variable in clinical presentation and treatment response. Traditionally used treatments for gMG are broadly immunosuppressive, do not target pathogenic immunoglobulin G (IgG) autoantibodies, and provide insufficient symptom relief with significant side effects. Fortunately, advances in the understanding of gMG pathogenesis are leading to the development of new treatment options, including neonatal Fc receptor (FcRn) modulators such as the recently approved efgartigimod, and rozanolixizumab, which recently...